Early Trial Finds New MS Cell Therapy Safe
Adults with progressive multiple sclerosis saw no serious dose-related side effects in a small, early-phase study.
Updated on Nov. 6, 2026 in Alzheimer’s

A Phase I trial found that azercabtagene zapreleucel (azer-cel), an off-the-shelf CAR T cell therapy, was safe in 18 adults with progressive multiple sclerosis. The data were presented October 21-23, 2026, at MSToronto2026 in Toronto, Canada, and are most relevant to people living with progressive forms of the disease.
Why it matters
Progressive multiple sclerosis has few treatment options that slow disability once it begins, so an early safety signal for a new cell-based approach is a step researchers track closely. The findings also show how a therapy designed to reset immune activity might be tested in this population before larger studies begin.
This Phase I open-label trial enrolled 18 adults with refractory progressive multiple sclerosis and reported a 102-day median follow-up. Most participants remained stable or improved on biomarker and disability measures, but the small, uncontrolled design means these results are preliminary.
The details
Participants first received lymphodepletion, a step that temporarily reduces existing immune cells, followed by a single infusion of azer-cel. Azer-cel is an off-the-shelf, allogeneic anti-CD19 CAR T cell therapy, meaning it is made from donor cells rather than each patient's own cells. It is designed to deplete peripheral B cells and then allow the immune system to rebuild, which researchers hypothesize may alter the immune activity driving the disease.
Timeline
Data were presented October 21-23, 2026, at MSToronto2026 in Toronto, Canada.
Participants were followed for a median of 102 days after treatment.
Health Landscape
Current disease-modifying treatments for multiple sclerosis work best in relapsing forms, leaving progressive disease with fewer proven options. Early-phase cell therapy studies like this one are testing whether immune reset approaches can reach that unmet need.
If you live with progressive multiple sclerosis, this early safety data is worth discussing with your neurologist as research into new options continues. Trial results like these are not yet a treatment recommendation, so current care decisions should stay within your clinical team's guidance.
The takeaway
Early safety signals for a new immune-based approach offer cautious hope for progressive multiple sclerosis, where options remain limited. Ask your neurologist whether ongoing clinical trials might be appropriate for your situation.
Further reading
For more on related neurological research, explore our coverage of Alzheimer’s.
Source note: This article includes information reported by Nature.


